Award-winning IRO Julie Dewey joins Nevro to head up IR and corporate communications

Dec 03, 2020
Dewey won IR Magazine Award for best IRO at a small cap five years in a row

Nevro, the US-listed medical device company, has appointed award-winning IR professional Julie Dewey as its vice president of investor relations and corporate communications.

Most recently, Dewey worked as senior vice president and chief communications officer at Wright Medical Group, which was acquired by Stryker last month.

During her nine years with Wright Medical, she won numerous investor relations awards from IR Magazine, including best IRO at a small cap for five consecutive years between 2014 and 2018. 

In 2018, she was also selected as one of IR Magazine’s 30 stars over 30 years, an initiative that celebrated leading IR professionals from the previous three decades.

During her career, Dewey has been heavily involved with NIRI, the US IR association. She sat on the board of directors between 2016 and 2019 and was among the first class that earned the association’s Investor Relations Charter four years ago.

Speaking to IR Magazine, she says she has worked with Nevro’s chairman and CEO – Keith Grossman – at a previous company, a factor that influenced her decision to take up the new role.

‘The opportunity to work with Keith again and the talented management team at Nevro, which is in a really exciting phase in its growth trajectory, was very attractive,’ she says.

Dewey says her initial objectives at Nevro are to grow the company’s IR outreach, strengthen its brand among the investment community and support the chief financial officer, Roderick MacLeod, who is in his first CFO position at a public company.

To do that, she will draw on 15 years of experience in IR and communications roles at medical device companies. As well as Wright Medical, she has worked as chief communications officer at Epocrates, ev3 and Kyphon.

 ‘At the companies I’ve been fortunate to work for over the years, I’ve been able to deal with – for the most part – the same investors and sell-side analysts. So over this long period of time, you can develop deep and productive relationships,’ Dewey says. 

‘I’ve seen and had to deal with a lot: good times, bad times, management team transitions, divestitures, acquisitions, product recalls, FDA approvals, litigation and financings. All of that experience certainly helps you in a new role because it isn’t the first time you’ve seen and dealt with those things.’

Sign up to get stories direct to your inbox
logo-black logo-black